Insider Transactions in Q1 2024 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,754
+24.84%
|
-
|
|
Mar 01
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,741
+22.14%
|
-
|
|
Mar 01
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+26.15%
|
-
|
|
Mar 01
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,751
+32.24%
|
-
|
|
Feb 29
2024
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
30,000
-56.94%
|
$4,590,000
$153.11 P/Share
|
|
Feb 29
2024
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$1,770,000
$59.25 P/Share
|
|
Feb 28
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
SELL
Open market or private sale
|
Direct |
329
-1.51%
|
$51,324
$156.35 P/Share
|
|
Feb 28
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
501
-1.8%
|
$78,156
$156.35 P/Share
|
|
Feb 28
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
574
-1.27%
|
$89,544
$156.35 P/Share
|
|
Feb 28
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,932
-1.17%
|
$457,392
$156.35 P/Share
|
|
Feb 28
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
574
-0.58%
|
$89,544
$156.35 P/Share
|
|
Feb 27
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
878
+16.44%
|
-
|
|
Feb 27
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+22.51%
|
-
|
|
Feb 27
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+17.12%
|
-
|
|
Feb 27
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,921
+10.39%
|
-
|
|
Feb 27
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+8.69%
|
-
|
|
Feb 16
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,030
-4.68%
|
$1,040,440
$148.26 P/Share
|
|
Feb 16
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,009
-7.06%
|
$149,332
$148.26 P/Share
|
|
Feb 16
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,007
-1.78%
|
$149,036
$148.26 P/Share
|
|
Feb 16
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,308
-5.29%
|
$193,584
$148.26 P/Share
|
|
Feb 15
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,953
+24.53%
|
-
|
|
Feb 15
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+39.22%
|
-
|
|
Feb 15
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,278
+14.62%
|
-
|
|
Feb 15
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,295
+33.2%
|
-
|
|
Feb 02
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,591
-11.41%
|
$272,061
$171.18 P/Share
|
|
Feb 01
2024
|
Indrani Lall Franchini EVP, CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,175
+50.0%
|
-
|